TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study 

CNS Pharmaceuticals (NASDAQ: CNSP) reported third-quarter 2025 results and highlighted continued progress with TPI 287, its blood-brain barrier–permeable abeotaxane in development for glioblastoma and other CNS tumors. The Company noted Phase 1 data showing potential BBB penetration and tumor responses, including 3 complete and 9 partial responses among 23 evaluable patients treated with TPI 287 plus bevacizumab, and plans to engage the FDA early next year on a registration-focused Phase 2 trial design in recurrent GBM. For the quarter, CNS reported a net loss of $3.3 million, R&D expenses of $2.2 million and G&A expenses of $1.1 million, ending the period with $9.9 million in cash, which is expected to fund operations into the second half of 2026.

To view the full press release, visit https://ibn.fm/L6OE6

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The Company’s drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Alex Pearon

Share
Published by
Alex Pearon
Breaks Categories: News

Recent Posts

TinyGemsBreaks – Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) Adds Chemical AI Risk Evaluator to Reactosphere Platform

This article has been disseminated on behalf of Redwood AI Corp. and may include paid…

3 days ago

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Confirms Atlas One Data Center Designed to Operate Independently of Texas Power Grid 

AZIO AI Holdings (NASDAQ: AZIO) confirmed that Atlas One, the first campus under its Project…

6 days ago

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q3 2026 Revenue of $17.2 Million, TONMYA Sales Growth of 37%

Tonix Pharmaceuticals (NASDAQ: TNXP) announced financial results for the third quarter ended Sept. 30, 2026,…

1 week ago

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Advances Atlas One Development With Equipment Shipments Underway

AZIO AI Holdings (NASDAQ: AZIO) announced that equipment shipments are underway for its Atlas One…

1 week ago

TinyGemsBreaks – Uranium Energy Corp. (NYSE American: UEC) Secures Long-Term Uranium Supply Agreements for 1.1 Million Pounds

Uranium Energy (NYSE American: UEC) announced that its subsidiary, UEC US Uranium LLC, has entered…

2 weeks ago